Diagnostic Value of the Antiviral Protein MxA in Viral Respiratory Tract Infections

Every year, millions of people fall ill with respiratory infections that make breathing difficult and leave them feeling exhausted. When a patient arrives at a clinic with a fever, a cough, and a sore throat, doctors face a tricky puzzle: is the illness caused by a virus or by bacteria? This distinction is critical because the treatments are completely different. Antibiotics are powerful medicines designed to kill bacteria, but they have no effect on viruses. Yet, because the symptoms of viral and bacterial infections often look identical, doctors frequently prescribe antibiotics "just in case." This habit, while well-intentioned, contributes to a growing global crisis where bacteria evolve to resist these drugs, rendering them useless when they are truly needed. To solve this, scientists have been searching for a reliable way to tell the two types of infections apart quickly and accurately, hoping to stop the misuse of antibiotics and protect the effectiveness of modern medicine.

The key to this puzzle lies in a specific protein produced by the human body itself, known as MxA. Think of MxA as a specialized security guard that the body's immune system deploys only when it detects a viral invader. When a virus enters the system, the body's defense mechanisms trigger the production of this protein to fight back. Bacteria, however, generally do not trigger this specific response. For a long time, doctors have relied on other markers, such as white blood cell counts or C-reactive protein, to guess the cause of an infection. These traditional markers act like general alarms that go off for many types of trouble, making it hard to distinguish between a viral and a bacterial emergency. The question researchers have been asking is whether MxA, with its specific focus on viruses, can serve as a more precise tool for diagnosis.

A team of researchers from hospitals in Guangxi, China, set out to test this idea in a large study involving nearly six hundred people. They recruited three distinct groups: healthy individuals who had no signs of illness, patients confirmed to have a viral respiratory infection, and patients confirmed to have a bacterial respiratory infection. To ensure the results were accurate, the team carefully screened everyone to exclude those with other chronic health issues or those who had recently taken antibiotics or antiviral medicines. For the patients, the researchers collected samples of blood to measure the levels of MxA, along with other common infection markers. They also took throat swabs or sputum samples to identify exactly which virus or bacteria was causing the sickness. The viral patients were tested for a wide range of common culprits, including influenza, respiratory syncytial virus, and the virus that causes COVID-19, while the bacterial patients were tested for specific bacterial strains.

The results of the study were striking. The researchers found that the levels of MxA in the blood of patients with viral infections were dramatically higher than in those with bacterial infections or in the healthy volunteers. In the group of people with confirmed viral infections, the median level of this protein was 173.84 nanograms per milliliter. In contrast, the healthy people had levels around 9.43 nanograms per milliliter, and the patients with bacterial infections had levels of only 17.74 nanograms per milliliter. This clear separation meant that MxA could effectively distinguish between the two types of illness. When the researchers analyzed the data to see how well MxA could act as a diagnostic tool, they calculated a score that reflected its accuracy. The protein proved to be a strong indicator, with an AUC of 0.81 when compared to bacterial ones. The team determined that a specific threshold of 68.405 nanograms per milliliter served as the best dividing line: levels above this point strongly suggested a viral cause, while levels below it pointed toward a bacterial one or no infection at all.

The study also looked at how well MxA performed when combined with other traditional markers, such as C-reactive protein and white blood cell counts. The researchers found that adding these other tests to MxA did not significantly improve the ability to tell the difference between viral and bacterial infections. The protein MxA alone carried most of the diagnostic weight, performing just as well as, or better than, the combination of all the other markers. Furthermore, the researchers examined whether the protein levels varied depending on which specific virus was causing the illness. They found that while the levels were high for all viral infections, they were highest in patients infected with respiratory syncytial virus, followed by influenza A, SARS-CoV-2, and human rhinovirus. Even with these variations, the levels for all viral groups remained far above the levels seen in bacterial infections, reinforcing the reliability of the test.

The researchers also noted that the protein levels behaved differently in children compared to adults. Children with viral infections showed even higher levels of MxA than adults with the same infections, likely because their immune systems respond more vigorously to viral threats. This suggests that while MxA is a powerful tool for everyone, doctors might eventually need to use slightly different reference points for children and adults to get the most accurate results. Despite these nuances, the study concluded that MxA is a highly effective biomarker. It offers a way to quickly identify when an antibiotic is not needed, helping to prevent the overuse of these drugs. By providing a clearer picture of what is actually causing a patient's illness, this protein could become a standard part of medical practice, guiding doctors to make better decisions and helping to preserve the power of antibiotics for the future.